Roche/Ipsen Plan 2010 Filing For Once-Weekly GLP-1 Analog
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies pitting once-weekly taspoglutide against Lilly's Byetta and Merck's Januvia commence in the second half.
You may also be interested in...
Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D
Emisphere carrier technology may be applied to other compounds as well.
Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D
Emisphere carrier technology may be applied to other compounds as well.
Amylin’s Byetta LAR Lowers Glucose, Weight
Diabetes market is big enough for liraglutide and other drugs, Amylin CEO tells “The Pink Sheet” DAILY.